In a report released on February 20, Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report), with a price target of $72.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jonathan Chang’s rating is based on Zai Lab’s promising developments in their ZL-1310 program, which targets small-cell lung cancer (SCLC). The initial monotherapy dose-escalation data for ZL-1310, presented at the 2024 EORTC-NCI-AACR symposium, showed impressive results, reinforcing confidence in its future potential. Zai Lab holds global rights to ZL-1310 and is actively engaged in phase I dose-escalation studies, both as a monotherapy and in combination settings, which are expected to yield further updates in the near term.
Additionally, Jonathan Chang highlights Zai Lab’s strategic positioning with ZL-1310 in the competitive landscape of DLL3 ADCs and B7-H3 ADCs. The company’s collaboration with MediLink Therapeutics adds value through a partly derisked ADC platform, supporting faster development timelines. Zai Lab’s broader pipeline and experienced management team further bolster confidence in their capacity to shift from a regional player to a strong global contender, potentially achieving FDA accelerated approval for ZL-1310 in 2L+ SCLC by 2027.
ZLAB’s price has also changed dramatically for the past six months – from $17.090 to $30.990, which is a 81.33% increase.